This shift is characterized by the up-regulation of pro-inflammatory cytokines such as IL-6 and TNF-α, which have anti-tumor properties, and the down-regulation of immunosuppressive cytokines such as IL-10 and TGF-β [31]. The gene discussed is TGFB1; the disease is neoplasm.